FDAnews
www.fdanews.com/articles/195727-allergan-sheds-brazikumab-zenpep-ahead-of-abbvie-merger

Allergan Sheds Brazikumab, Zenpep Ahead of AbbVie Merger

February 3, 2020

Allergan agreed to sell off its investigational drug brazikumab and its pancreatic enzyme drug Zenpep (pancrelipase) to clear the way for its proposed $63 billion acquisition by AbbVie.

Under the agreement, AstraZeneca (AZ) will regain brazikumab, an IL-23 inhibitor candidate currently in development for Crohn’s disease and ulcerative colitis. AZ previously sold the treatment to Allergan in October 2016 for $250 million, with additional payments of up to $1.27 billion, depending on achievements.

The divestment deal — which requires the FTC’s approval — also delivers Allergan’s Zenpep and a non-enteric coated pancreatic enzyme preparation, Viokace (pancrelipase), to Nestlé.

View today's stories